Healthleap, a startup developing an artificial intelligence platform that analyzes patient records to flag individuals at risk of undiagnosed illnesses, has secured $38 million in combined seed and Series A funding. The investment round was co-led by Sequoia Capital and First Round Capital with an $8 million seed component, followed by a $30 million Series A led by Hummingbird Ventures. The company declined to disclose its current valuation.
Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, the company initially launched a clinical nutrition tool designed by Jemima for dietitians. The firm later pivoted to create a broader platform aimed at detecting conditions such as malnutrition and delirium in hospitalized patients, which are frequently missed during initial admissions. CEO and co-founder Josiah Meyer highlighted that while structured data like labs and vitals are easily accessible, critical indicators often reside in unstructured clinical notes.
“A patient’s chart holds two kinds of data. Labs, weights, and vital signs sit in structured fields, but the most telling signs sit in clinicians’ written notes: poor appetite, recent weight loss, muscle loss, trouble swallowing,” Meyer explained. “Our developing approach is extracting affirmative or negated mentions of these clinical concepts in an easily extensible and scalable way.”
The platform currently operates in over 50 hospitals, including major U.S. health systems such as Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. In addition to screening for malnutrition and delirium, the company has developed programs to identify aspiration pneumonia, pressure ulcers, and readmission risks for congestive heart failure, which are currently undergoing clinical validation.
Healthleap integrates directly with hospital electronic health record systems, utilizing language models to extract insights from written notes and combining them with structured data to generate risk scores. The software does not provide diagnoses but instead surfaces alerts for care teams within their existing workflows each morning. According to Meyer, the system analyzes every adult inpatient’s record nightly, incorporating lab results, medications, diet orders, and clinician notes.
The focus on malnutrition stems from its high prevalence and significant impact on patient outcomes. Research indicates that 20% to 50% of hospital inpatients suffer from malnutrition, a condition linked to prolonged stays, impaired wound healing, infections, and increased mortality. Over the past year, Healthleap has grown its customer base from three hospital partners to more than 50, with revenue increasing more than tenfold.
The company employs a pricing model based on three-year contracts tied to a hospital’s licensed bed count, supplemented by outcome-based structures. Meyer stated that Healthleap guarantees measurable return on investment (ROI) multiples of the contract price, noting that all customers have achieved at least a 5x hard ROI, with some exceeding 20x annual total ROI.
At the Hospital of the University of Pennsylvania, the malnutrition program generated $23.8 million in annualized financial impact, comprising $6.3 million in additional reimbursements and $17.5 million derived from reduced lengths of stay.
Healthleap intends to use the new capital to bolster its engineering, product, sales, and customer success teams as it adds support for additional conditions. The company aims to eventually cover more than 40 major health conditions and expand its services into outpatient and home care settings.
Sequoia backing is solid, but scaling this across 40 conditions sounds like a massive engineering undertaking. Cautiously optimistic.
Unstructured notes hold the real goldmine. Great pivot from nutrition to broader risk detection.
Fifteen times ROI is impressive. Hospitals finally need tools that prove their worth financially, not just clinically.